Purpose
To monitor the trends in incidence and prevalence of infectious diseases of public health importance.
Key Information
Infectious disease data, including demographics, geographic, and seasonal distribution of reportable diseases.
Collection Period
2018-2024
Rhode Island Numbers
| Disease: Probable and Confirmed Counts Only | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Acute Flaccid Myelitis | 1 | 0 | 0 | ||||
| Alpha-Gal Syndrome | 3 | 5 | 4 | 11 | 6 | 7 | |
| Anaplasmosis | 149 | 151 | 91 | 140 | 63 | 84 | 86 |
| Babesiosis | 165 | 158 | 193 | 195 | 118 | 242 | 161 |
| Candida auris, Clinical | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Candida auris, Colonized | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Campylobacteriosis about | data | 326 | 355 | 206 | 278 | 249 | 275 | 361 |
| Carapenmase Producing Organisms (CPO's), Clinical | 9 | 15 | 22 | 14 | 25 | 31 | 24 |
| Carapenmase Producing Organisms (CPO's), Colonized | 0 | 2 | 46 | 0 | 31 | 13 | 14 |
| Carbapenem Resistant Enterobacteriaceae (CRE) | 22 | 26 | 20 | 26 | 20 | 30 | 43 |
| Carbapenem Resistant Organisms (CRO) | 42 | 79 | 66 | 61 | 66 | 95 | 94 |
| Chikungunya | 0 | 1 | 0 | 0 | 0 | 1 | 1 |
| Chlamydia | 5,487 | 5,717 | 4,714 | 5,199 | 5,224 | 5,269 | 4,681 |
| Coccidioidomycosis | 4 | 1 | 0 | 1 | 1 | 2 | 2 |
| COVID-19 (SARS-CoV-2) | 86,882 | 140,322 | 198,751 | 32,821 | N/A | ||
| CJD (non-variant) | 4 | 3 | 0 | 0 | 0 | 0 | 0 |
| Cryptosporidosis | 90 | 63 | 23 | 34 | 62 | 61 | 38 |
| Cyclosporiasis | 3 | 31 | 4 | 4 | 2 | 7 | 12 |
| Eastern Equine Encephalitis | 0 | 3 | 0 | 0 | 0 | 0 | 1 |
| Ehrlichiosis | 79 | 45 | 19 | 15 | 16 | 6 | 4 |
| Giardiasis data | 56 | 79 | 31 | 55 | 59 | 65 | 92 |
| Gonorrhea | 1,336 | 1,516 | 1,399 | 1,681 | 1,444 | 1,672 | 1,622 |
| Haemophilus Influenzae, invasive | 25 | 24 | 12 | 15 | 8 | 22 | 22 |
| Hepatitis A | 7 | 6 | 4 | 1 | 4 | 4 | 3 |
| Hepatitis B acute data | 1 | 5 | 10 | ||||
| Hepatitis B chronic data | 553 | 384 | 333 | ||||
| Hepatitis C acute data | 16 | 23 | 18 | ||||
| Hepatitis C chronic data | 1,118 | 798 | 470 | ||||
| Histoplasmosis | 0 | 0 | 0 | 0 | 1 | 2 | 1 |
| HIV (Human Immunodeficiency Virus) | 70 | 70 | 54 | 69 | 69 | 70 | 94 |
| Jamestown Canyon Virus | 0 | 0 | 0 | 1 | 2 | 0 | 1 |
| Legionellosis data | 73 | 48 | 36 | 87 | 60 | 55 | 26 |
| Listeriosis data | 7 | 2 | 5 | 6 | 6 | 5 | 4 |
| Lyme Disease 2 | 1,111 | 971 | 839 | 980 | 2,326 | 2,852 | 2,563 |
| Malaria | 12 | 13 | 2 | 7 | 10 | 14 | 7 |
| Measles | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Meningococcal Disease, invasive | 1 | 3 | 0 | 0 | 0 | 2 | 0 |
| Mpox | 84 | 4 | 8 | ||||
| Multisystem Inflammatory Syndrome Associated with COVID-19 (MIS-C) | 12 | 18 | 8 | 0 | 1 | ||
| Mumps | 5 | 9 | 0 | 2 | 2 | 4 | 4 |
| Pertussis | 34 | 44 | 4 | 0 | 0 | 3 | 243 |
| Invasive Pneumococcal Disease | 59 | 85 | 51 | 32 | 79 | 83 | 88 |
| Powassan Virus | 0 | 1 | 0 | 1 | 0 | 1 | 2 |
| Spotted Fever Rickettsiosis (including Rocky Mountain Spotted Fever) | 9 | 0 | 0 | 1 | 0 | 0 | 1 |
| Rubella (including congenital) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Salmonellosis data | 175 | 152 | 115 | 137 | 147 | 184 | 201 |
| Shiga-toxin positive E. coli data | 45 | 48 | 28 | 45 | 42 | 56 | 69 |
| Shigellosis data | 59 | 85 | 32 | 49 | 62 | 97 | 121 |
| Streptococcus, Group A data | 43 | 53 | 34 | 30 | 40 | 83 | 106 |
| Streptococcus, Group B | 114 | 90 | 101 | 135 | 108 | 118 | 138 |
| Syphilis (congenital) | 0 | 0 | 1 | 2 | 5 | 2 | 2 |
| Syphilis (late) | 118 | 213 | 128 | 237 | 270 | 260 | 321 |
| Syphilis (primary, secondary, and early latent) data | 167 | 210 | 186 | 328 | 240 | 190 | 161 |
| Tuberculosis | 19 | 14 | 7 | 17 | 17 | 27 | 23 |
| Varicella | 67 | 64 | 32 | 32 | 42 | 34 | 41 |
| Vibriosis | 13 | 12 | 10 | 13 | 12 | 24 | 22 |
| West Nile Virus | 1 | 0 | 0 | 2 | 1 | 1 | 6 |
| Yersiniosis (non-pestis) | 27 | 41 | 45 |
Footnotes:
1: 2024 preliminary data was extracted from the RI National Electronic Disease Surveillance System (NEDSS) in August 2025, and is subject to change.
2: The CSTE Lyme disease case definition was changed for the start of the 2022 reporting year. Rhode Island is a high incidence state for Lyme disease and is reporting based on laboratory data per the new case definition.
The new Lyme disease case definition can be viewed on the CDC wepage: https://ndc.services.cdc.gov/case-definitions/lyme-disease-2022/